ABOUT US
About Company
Investors
CSR
PIPELINE
CDP
Product
Publication
NEWS
Corporate News
Media Reports
CAREER
Talents Value
Talents Acquisition
CONTACTS
中文
/
en
ABOUT US
About Company
Investors
CSR
PIPELINE
CDP
Product
Publication
NEWS
Corporate News
Media Reports
CAREER
Talents Value
Talents Acquisition
CONTACTS
Phone: +86 21 63862192
Mailbox: info@alphabiopharma.com
Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai
Beijing: Room 2512, The Place Tower, No. 9 Guanghua Road, Chaoyang District, Beijing
Share :
NEWS
Corporate News
Corporate News
Media Reports
NEWS
05/31
2023
Ongoing Clinical Challenge: T...
Professor Wu Yilong will bring EVEREST study landing in this year's A...
view more
05/15
2023
Ongoing Clinical Challenge: T...
EGFR-TKI therapy for EGFR-mutated NSCLC patients with CNS met...
view more
01/30
2023
CDE Accepted Alpha Biophar...
Zorifertinib, a next-generation EGFR-TKI specially designed to treat adv...
view more
01/29
2023
Wugen Presents Data on WU-N...
WU-NK-101 overcomes limitations encountered with other adoptive cell therapi...
view more
12/15
2022
Wugen Presents Data Supporti...
Genetic tumor microenvironment (TME) signature identified as highly predicti...
view more
07/20
2022
Wugen Receives U.S. FDA F...
Wugen today announced that the U.S. Food and Drug Administration (FDA) ...
view more
06/11
2022
Wugen Presents New Preclinic...
Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of o...
view more
03/16
2022
Wugen Announces First Patien...
WU-CART-007 granted FDA Orphan Drug Designation for the treatment of...
view more
09/18
2021
Immunotherapy product developme...
On September 18, 2021, Alpha Biopharma announced that its immunotherapy prod...
view more
1
2